Group 1 - The core point of the article is the appointment of Wang Min as the acting chairman of the board and the acting chairman of the nomination committee of Yuehai Investment, effective immediately after the relevant board meeting on March 30, 2026 [1]

Core Viewpoint - The article reports that Xie Qirun, the executive director and chairman of China Biologic Products Holdings (01177.HK), has increased his shareholding in the company, indicating confidence in its future performance [1] Group 1: Shareholding Increase - On March 30, 2026, Xie Qirun purchased 1.748 million shares at an average price of HKD 5.73 per share, totaling approximately HKD 10.016 million [1] - Following this transaction, Xie Qirun's total shareholding increased to 7.748 million shares, raising his ownership percentage from 0.03% to 0.04% [1]

Core Viewpoint - Kailaiying (002821.SZ) reported a total operating revenue of 6.67 billion yuan for the year 2025, reflecting a year-on-year growth of 14.91% and a constant currency growth of 16.78% [1] Financial Performance - The company achieved revenue of 2.04 billion yuan in the fourth quarter, representing a quarter-on-quarter increase of 41.53% and a year-on-year increase of 22.59%, with a constant currency growth of 30.84% [1] - The net profit attributable to shareholders reached 1.13 billion yuan, marking a year-on-year increase of 19.35% [1] - Adjusted net profit was reported at 1.25 billion yuan, showing a significant year-on-year growth of 56.09% [1] Shareholder Returns - The company declared a cash dividend of 13 yuan for every 10 shares to all shareholders [1]

格隆汇3月30日丨亨得利(03389.HK)公告，截至2025年12月31日止年度，本集团收入录得6.49亿元(人民 币，下同)(2024年：10.44亿元)，较去年同期下降37.8%；股份持有人应占亏损为人民币2690万元(2024 年：亏损人民币6516万元)，较去年同期下降了58.7%。年度亏损的主要原因是：销售下降，应占联营公 司转盈为亏，银行利息收入下降，叠加对应收账款拨备等综合因素影响。 ...

格隆汇3月30日丨理想汽车-W(02015.HK)公告，3月30日耗资7158.6万港元回购104.4万股。 ...

Group 1 - The company achieved a contract sales amount attributable to shareholders of approximately RMB 33.01 billion, with a corresponding contract sales area of about 4.02 million square meters for the year ending December 31, 2025 [1][2] - Total revenue for the year was approximately RMB 154.89 billion, representing a year-on-year decrease of about 38.7% [1] - The net profit for the year was approximately RMB 1.62 billion, with a net profit attributable to shareholders of approximately RMB 3.26 billion [1] Group 2 - The company prioritizes stable and sustainable operations, with a unified and stable core management team [2] - Administrative expenses and marketing costs decreased by 15.7% year-on-year, reflecting improved operational efficiency [2] - The company aims to maintain positive operating cash flow and gradually restore normal operations, leveraging experience from "guaranteeing housing delivery" initiatives [2]

Core Viewpoint - China Galaxy (06881.HK) announced the appointment of executive director Qu Yanping as a member of the Board's Compliance and Risk Management Committee, effective from March 30, 2026 [1] Group 1 - The appointment of Qu Yanping is aimed at enhancing the governance structure of the company [1]

Core Viewpoint - Kuaishou Technology (01024.HK) announced a share buyback of 1.885 million shares at a cost of HKD 84.592 million on March 30 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was approximately HKD 84.592 million, reflecting the company's financial strategy [1] - The number of shares repurchased was 1.885 million, which may influence the stock's market performance [1]

Core Viewpoint - Minmetals Holdings (01999.HK) announced a board meeting scheduled for May 15, 2026, to consider and approve the audited financial performance for the year ending March 31, 2026, as well as to discuss the declaration of a final dividend, if any, and other matters [1] Group 1 - The board meeting will focus on the audited financial results for the fiscal year ending March 31, 2026 [1] - The meeting will also consider the declaration of a final dividend [1] - Additional matters will be addressed during the board meeting [1]

Core Viewpoint - Fangda Holdings (01521.HK) reported a slight increase in revenue for the fiscal year ending December 31, 2025, with earnings rising from approximately $255 million to about $257 million, reflecting a 0.7% growth. The net profit surged to around $6.8 million, a significant increase of 1033.3% compared to the previous year's net profit of approximately $600,000. Basic earnings per share stood at $0.0034 [1]. Revenue Performance - The group's revenue for the fiscal year ending December 31, 2025, increased to approximately $257 million from about $255 million for the fiscal year ending December 31, 2024, marking a 0.7% growth [1]. - The net profit for the fiscal year ending December 31, 2025, was approximately $6.8 million, a substantial rise of 1033.3% from the net profit of around $600,000 for the fiscal year ending December 31, 2024 [1]. Business Segment Analysis - Revenue from North America and Europe experienced a slight decline, primarily due to decreased earnings from the drug discovery business, which was negatively impacted by pharmaceutical and biotechnology companies optimizing their R&D portfolios and cautiously controlling development expenditures [1]. - However, strong demand for laboratory testing services partially offset the decline in revenue from the drug discovery segment [1].